Smith & Nephew SNATS (NYSE:SNN) Upgraded to Strong-Buy at Kepler Capital Markets

Smith & Nephew SNATS (NYSE:SNN) was upgraded by Kepler Capital Markets to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 3rd. Canaccord Genuity Group dropped their price target on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Sanford C. Bernstein set a $37.50 target price on Smith & Nephew SNATS and gave the stock a “market perform” rating in a research report on Tuesday, October 14th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Smith & Nephew SNATS in a research note on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Stock Performance

Smith & Nephew SNATS stock opened at $32.56 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. The business has a 50 day simple moving average of $35.79 and a 200-day simple moving average of $33.16. Smith & Nephew SNATS has a 12 month low of $23.69 and a 12 month high of $38.79.

Institutional Investors Weigh In On Smith & Nephew SNATS

Institutional investors have recently modified their holdings of the company. Cerity Partners LLC increased its stake in Smith & Nephew SNATS by 207.3% in the 1st quarter. Cerity Partners LLC now owns 31,020 shares of the medical equipment provider’s stock valued at $880,000 after purchasing an additional 20,926 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Smith & Nephew SNATS in the first quarter valued at $570,000. Cetera Investment Advisers increased its position in shares of Smith & Nephew SNATS by 8.9% in the first quarter. Cetera Investment Advisers now owns 16,748 shares of the medical equipment provider’s stock valued at $475,000 after buying an additional 1,373 shares in the last quarter. Richards Merrill & Peterson Inc. raised its stake in shares of Smith & Nephew SNATS by 500.0% during the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 1,000 shares during the last quarter. Finally, Pinnacle West Asset Management Inc. boosted its position in shares of Smith & Nephew SNATS by 10.9% in the 1st quarter. Pinnacle West Asset Management Inc. now owns 10,175 shares of the medical equipment provider’s stock worth $289,000 after buying an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.